Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pastuszak

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Canadian Family Physician Medecin De Famille Canadien|February 1, 1997
How to ensure fetal safety when mothers use isotretinoin (Accutane)G Koren, A Pastuszak
Pediatric Research|May 1, 1990
Medical research in infants and children in the eighties: analysis of rejected protocolsG Koren, A Pastuszak
Teratology|June 1, 1990
Prevention of unnecessary pregnancy terminations by counselling women on drug, chemical, and radiation exposure during the first trimesterG Koren, A Pastuszak
The New England Journal of Medicine|April 17, 1998
Drugs in pregnancyG Koren, A Pastuszak, S Ito
Reproductive Toxicology (Elmsford, N.Y.)|January 1, 1991
Fetal outcome following intrauterine amantadine exposureM Levy, A Pastuszak, G Koren
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|May 1, 1991
Women's perception of teratogenic riskG Koren, M Bologa, A Pastuszak
Annals of the New York Academy of Sciences|March 15, 1993
How women perceive teratogenic risk and what they do about itG Koren, M Bologa, A Pastuszak
American Journal of Perinatology|September 1, 1993
Pregnancy outcome following fetal exposure to tiaprofenic acid in the first trimesterA Pastuszak, M Pinelli, G Koren
Canadian Family Physician Medecin De Famille Canadien|January 14, 1998
Taking folic acid during pregnancy. Don't leave it too lateD Kennedy, A Pastuszak, G Koren
Reproductive Toxicology (Elmsford, N.Y.)|January 1, 1994
Use of the Retinoid Pregnancy Prevention Program in Canada: patterns of contraception use in women treated with isotretinoin and etretinateA Pastuszak, G Koren, M J Rieder
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Canadian Family Physician Medecin De Famille Canadien|February 1, 1997
How to ensure fetal safety when mothers use isotretinoin (Accutane)G Koren, A Pastuszak
Pediatric Research|May 1, 1990
Medical research in infants and children in the eighties: analysis of rejected protocolsG Koren, A Pastuszak
Teratology|June 1, 1990
Prevention of unnecessary pregnancy terminations by counselling women on drug, chemical, and radiation exposure during the first trimesterG Koren, A Pastuszak
The New England Journal of Medicine|April 17, 1998
Drugs in pregnancyG Koren, A Pastuszak, S Ito
Reproductive Toxicology (Elmsford, N.Y.)|January 1, 1991
Fetal outcome following intrauterine amantadine exposureM Levy, A Pastuszak, G Koren
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|May 1, 1991
Women's perception of teratogenic riskG Koren, M Bologa, A Pastuszak
Annals of the New York Academy of Sciences|March 15, 1993
How women perceive teratogenic risk and what they do about itG Koren, M Bologa, A Pastuszak
American Journal of Perinatology|September 1, 1993
Pregnancy outcome following fetal exposure to tiaprofenic acid in the first trimesterA Pastuszak, M Pinelli, G Koren
Canadian Family Physician Medecin De Famille Canadien|January 14, 1998
Taking folic acid during pregnancy. Don't leave it too lateD Kennedy, A Pastuszak, G Koren
Reproductive Toxicology (Elmsford, N.Y.)|January 1, 1994
Use of the Retinoid Pregnancy Prevention Program in Canada: patterns of contraception use in women treated with isotretinoin and etretinateA Pastuszak, G Koren, M J Rieder
Pageof 4